Fariba Behnia-Willison
Fariba Behnia-Willison has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Derek Abbott
The University of Adelaide
1 shared publication - Johnny Yi
Department of Medical and Surgical Gynecology, Mayo Clinic, Phoenix, USA
1 shared publication - Nadia Willison
Discipline of Biomedical Engineering, School of Electrical and Mechanical Engineering, University of Adelaide, Adelaide, Australia
1 shared publication - Negin Mirzaei Damabi
Adelaide South Australia 5000 The University of Adelaide School of Public Health
1 shared publication - Pouria Aryan
School of Mechanical Engineering University of Adelaide Adelaide Australia
1 shared publication - Rituparna Dutta
FBW Gynaecology Plus, Ashford, SA 5035, Australia
1 shared publication
Latest Publications
- Open Access
- 18 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5832
Application of Platelet-Rich Plasma in Gynaecologic Disorders: A Scoping Review
Platelet-rich plasma (PRP) therapy is a non-invasive, autologous treatment with regenerative potential in gynaecology beyond fertility applications. This review evaluates PRP in non-fertility-related gynaecological conditions affecting women’s quality of life (QoL). Methods: Following PRISMA-ScR guidelines, we searched Embase, CINAHL, Web of Science, Scopus, CENTRAL, and MEDLINE for studies on PRP in conditions such as vulvar lichen sclerosus (VLS), vulvovaginal atrophy (VVA), sexual dysfunction (SD), stress urinary incontinence (SUI), and interstitial cystitis/bladder pain syndrome (IC/BPS). Of 3660 records screened, 43 studies (randomised controlled trials, quasi-experimental, cohort, and case series) were included. Results: PRP improved symptoms and QoL in several conditions, particularly VLS and SD, and was generally well tolerated with minor adverse effects (e.g., injection-site pain, transient discomfort). Evidence for abnormal uterine bleeding (AUB) and pelvic organ prolapse (POP) was inconclusive. Considerable heterogeneity in preparation protocols and outcome measures limited cross-study comparison. Conclusions: PRP shows promise as a minimally invasive therapy for certain gynaecological conditions. Standardisation of preparation and administration, along with large-scale RCTs, is needed to determine long-term efficacy and safety.
- 18 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5832
Open AccessApplication of Platelet-Rich Plasma in Gynaecologic Disorders: A Scoping Review
Platelet-rich plasma (PRP) therapy is a non-invasive, autologous treatment with regenerative potential in gynaecology beyond fertility applications. This review evaluates PRP in non-fertility-related gynaecological conditions affecting women’s quality of life (QoL). Methods: Following PRISMA-ScR guidelines, we searched Embase, CINAHL, Web of Science, Scopus, CENTRAL, and MEDLINE for studies on PRP in conditions such as vulvar lichen sclerosus (VLS), vulvovaginal atrophy (VVA), sexual dysfunction (SD), stress urinary incontinence (SUI), and interstitial cystitis/bladder pain syndrome (IC/BPS). Of 3660 records screened, 43 studies (randomised controlled trials, quasi-experimental, cohort, and case series) were included. Results: PRP improved symptoms and QoL in several conditions, particularly VLS and SD, and was generally well tolerated with minor adverse effects (e.g., injection-site pain, transient discomfort). Evidence for abnormal uterine bleeding (AUB) and pelvic organ prolapse (POP) was inconclusive. Considerable heterogeneity in preparation protocols and outcome measures limited cross-study comparison. Conclusions: PRP shows promise as a minimally invasive therapy for certain gynaecological conditions. Standardisation of preparation and administration, along with large-scale RCTs, is needed to determine long-term efficacy and safety.